@inproceedings{alcantara:hal-04228460,
TITLE = {Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL)},
AUTHOR = {Alcantara, Marion and Chevrier, Marion and Jardin, Fabrice and Schmitt, Anna and Houillier, Caroline and Oberic, Lucie and Chinot, Olivier L. and Morschhauser, Franck and Peyrade, Frederic and Houot, Roch and Foulon, Christine and Chauvin, Estelle and Ghesquieres, Herve and Soussain, Carole},
URL = {https://hal.science/hal-04228460},
BOOK
TITLE = {2023 ASCO Annual Meeting},
ADDRESS = {Chicago, United States},
PUBLISHER = {LIPPINCOTT WILLIAMS and WILKINS},
SERIES = {JOURNAL OF CLINICAL ONCOLOGY},
VOLUME = {41},
NUMBER = {16\_suppl},
PAGES = {7566-7566},
YEAR = {2023},
MONTH = Jun, DOI = {10.1200/JCO.2023.41.16\_suppl.7566},
HAL_ID = {hal-04228460},
HAL_VERSION = {v1},
}